Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy.

Smentoch J, Szade J, Żaczek AJ, Eltze E, Semjonow A, Brandt B, Bednarz-Knoll N.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1356. doi: 10.3390/cancers11091356.

2.

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.

van Strijp D, de Witz C, Heitkötter B, Huss S, Bögemann M, Baillie GS, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2019 Jun 2;2019:8107807. doi: 10.1155/2019/8107807. eCollection 2019.

3.

Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer.

Eminaga O, Al-Hamad O, Boegemann M, Breil B, Semjonow A.

Health Informatics J. 2019 Jun 26:1460458219855884. doi: 10.1177/1460458219855884. [Epub ahead of print]

PMID:
31238766
4.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.

Erickson AM, Luzzago S, Semjonow A, Vasarainen H, Laajala TD, Musi G, de Cobelli O, Mirtti T, Rannikko A.

Eur Urol Oncol. 2018 Sep;1(4):268-275. doi: 10.1016/j.euo.2018.04.006. Epub 2018 May 15.

PMID:
31100247
5.

BRCAness in prostate cancer.

Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B.

Oncotarget. 2019 Mar 29;10(25):2421-2422. doi: 10.18632/oncotarget.26818. eCollection 2019 Mar 29. No abstract available.

6.

Development and Prospective Randomized Evaluation of a Decision Aid for Prostate-specific Antigen-based Early Detection of Prostate Cancer in Men Aged Between 55 and 69Yr: The PSAInForm Trial.

Semjonow A, Hense HW, Schlößler K, Simbrich A, Borowski M, Bothe C, Kruse K, Tiedje D, Kuss K, Adarkwah CC, Maisel P, Jendyk R, Kurosinski MA, Gerß J, Heidinger O, Tschuschke C, Becker R, Roobol MJ, Bangma C, Donner-Banzhoff N.

Eur Urol. 2019 Jul;76(1):1-3. doi: 10.1016/j.eururo.2019.01.008. Epub 2019 Jan 18.

PMID:
30665815
7.

Diagnostic Classification of Cystoscopic Images Using Deep Convolutional Neural Networks.

Eminaga O, Eminaga N, Semjonow A, Breil B.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00126.

8.

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ.

Eur Urol. 2019 Apr;75(4):558-561. doi: 10.1016/j.eururo.2018.10.047. Epub 2018 Nov 2.

PMID:
30396635
9.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.

Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N.

Transl Res. 2019 Jan;203:49-56. doi: 10.1016/j.trsl.2018.08.007. Epub 2018 Sep 12.

PMID:
30287243
10.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.

Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.

Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.

11.

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

van Strijp D, de Witz C, Vos PC, den Biezen-Timmermans E, van Brussel A, Wrobel J, Baillie GS, Tennstedt P, Schlomm T, Heitkötter B, Huss S, Bögemann M, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2018 Jul 26;2018:5821616. doi: 10.1155/2018/5821616. eCollection 2018.

12.

Discordant prostate specific antigen test results despite WHO assay standardization.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.

Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

PMID:
29734838
13.

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.

Boegemann M, Schlack K, Thomes S, Steinestel J, Rahbar K, Semjonow A, Schrader AJ, Aringer M, Krabbe LM.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E380. doi: 10.3390/ijms18020380.

14.

[Results of a psychooncological group intervention in male cancer patients aged 60 years or older].

Schneider G, Kropff B, Unrath M, Floeth S, Semjonow A, Doering S.

Z Psychosom Med Psychother. 2016 Dec;62(4):336-352. German. No abstract available.

PMID:
27924697
15.

Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.

Tolkach Y, Eminaga O, Wötzel F, Huss S, Bettendorf O, Eltze E, Abbas M, Imkamp F, Semjonow A.

Prostate. 2017 Mar;77(4):396-405. doi: 10.1002/pros.23278. Epub 2016 Nov 16.

PMID:
27862105
16.

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.

Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M.

Int J Mol Sci. 2016 Sep 9;17(9). pii: E1520. doi: 10.3390/ijms17091520.

17.

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.

Boegemann M, Schlack K, Fischer AK, Gerß J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM.

PLoS One. 2016 Sep 1;11(9):e0161959. doi: 10.1371/journal.pone.0161959. eCollection 2016.

18.

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.

Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, Semjonow A, Schrader AJ, Boegemann M.

BMC Cancer. 2016 Mar 14;16:214. doi: 10.1186/s12885-016-2260-y.

19.

Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.

Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M.

J Nucl Med. 2016 Apr;57(4):563-7. doi: 10.2967/jnumed.115.169243. Epub 2016 Jan 14.

20.

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.

BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12.

Supplemental Content

Loading ...
Support Center